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BACKGROUND: To evaluate the antitumour activity and safety of metronomic cyclophosphamide vs megestrol acetate in progressive
and advanced cancer patients having exhausted all effective therapies under standard care.
METHODS: Patients were randomly assigned to receive orally metronomic cyclophosphamide (50mg b.i.d) or megestrol acetate
(160mg only daily) until intolerance or progression (RECIST 1.0). The primary efficacy end point was a 2-month progression-free rate
(PFR2m). According to Optimal Simon’s design and the following assumptions, namely, P0¼5%, P1¼20%, a¼b¼10%, the
treatment is considered as effective if atleast 5 out of 44 patients achieved PFR2m.
RESULTS: Between September 2006 and January 2009, 88 patients were enrolled. Two patients experienced grade 3–4 toxicities in
each arm (4%). One toxic death occurred in the megestrol acetate arm as a consequence of thrombosis. The metronomic
cyclophosphamide arm reached the predefined level of efficacy with a PFR2m rate of 9 out of 44 and a PFR4m rate of 5 out of 44. The
MA arm failed to achieve the level of efficacy with a PFR2m of 4 out of 44 and a PFR4m of 1 out of 44. The median overall survival was
195 and 144 days in the metronomic cyclophosphamide arm and megestrol acetate arm, respectively.
CONCLUSION: Metronomic cyclophosphamide is well tolerated and provides stable disease in such vulnerable and poor-prognosis
cancer patients. This regimen warrants further evaluations.
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The care of cancer patients with a good performance status (PS)
but having exhausted all available effective therapies under
standard care represents a daily challenging situation for medical
oncologists. Three possibilities may be discussed: exclusive
palliative care, inclusion in phase I trials or treatment with a
non-validated regimen, sometimes without a strong scientific
basis. We know very well that a large proportion of such patients
are not eligible for contemporary phase I trials because of an
increasing number of eligibility criteria (Penel et al, 2008). Many
patients with a good PS are reluctant to accept palliative care
exclusively, and many medical oncologists are reluctant to propose
exclusive palliative care in patients having a good PS. Nevertheless,
the administration of an off-labeled chemotherapy regimen risks
exposing patients to unnecessary toxicity without reasonable hope
of clinical benefit, and unduly raises the cost of care. Considering
these facts and the common nature of this situation, we explored
different possibilities of treatment and retained metronomic
cyclophosphamide and megestrol acetate as valuable options
warranting further evaluation.
Metronomic chemotherapy refers to the frequent administration
of chemotherapy, often daily, with no prolonged drug-free breaks,
at doses significantly lower than the maximum tolerated dose
(Kerbel and Kamen, 2004). One of the most frequently explored
drugs for such uses is cyclophosphamide. In preclinical models,
the metronomic administration of this bifunctional alkylating
agent showed its ability to inhibit angiogenesis by inducing
pericytes and endothelial cell dysfunction and apoptosis (Browder
et al, 2000; Pietras and Hanahan, 2005; Yap et al, 2005). In
retrospective series or clinical studies, metronomic cyclopho-
sphamide alone or in combination provided some evidence of
efficacy in several types of cancers, such hormone-refractory
prostate cancer (Glode et al, 2003; Lord et al, 2007), heavily
pretreated sarcoma (Casanova et al, 2004; De Pas et al, 2004;
Stempak et al, 2006), ovarian cancer (Garcia et al, 2008) or breast
cancer (Colleoni et al, 2006; Dellapasqua et al, 2008).
Megestrol acetate is currently used to improve appetite and
increase weight in cancer-associated anorexia–cachexia syndrome
(Mantovani et al, 1998; Desport et al, 2000; Berenstein and Ortiz,
2005; Yavuzsen et al, 2005). In 1993, the US Federal Drug
Administration approved megestrol acetate for the treatment of
anorexia, cachexia or unexplained weight loss in patients with
AIDS. The mechanisms by which megestrol acetate increases
appetite is largely unknown, but some data suggest an action on
the pro-and anti-inflammatory interleukin network, especially a
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sreduction in circulating tumour necrosis factor-a (Mantovani et al,
1998). A large meta-analysis had recently shown its ability to
improve appetite and weight gain in cancer patients (Berenstein
and Ortiz, 2005), and one randomised clinical trial showed its
ability to improve the quality of life (Westman et al, 1999).
Nevertheless, some studies had also pointed out the risk of
phlebitis and pulmonary embolism related to MA (Rowland et al,
1996; Loprinzi et al, 1999). Furthermore, megestrol acetate had
provided anecdotal objective responses for some hormone-
independent solid tumours (Ravaud et al, 2008).
We carried out a multicentre randomised phase II trial to
evaluate the safety and efficacy of metronomic cyclophosphamide
vs megestrol acetate in cancer patients with a good PS and having
exhausted all available effective treatments under standard care.
PATIENTS AND METHODS
Inclusion criteria
Patients were eligible if they had biopsy-proven cancer, were at
least 18 years of age, had a good PS (p2), had exhausted all
effective or validated therapies under standard care (chemo-
therapy, immunotherapy, molecular-targeted therapy and hormonal
therapy), had progressive and measurable disease (according to
Response Evaluation Criteria in Solid Tumour (RECIST 1.0)
(Therasse et al, 2000)) before inclusion and were using effective
contraception. They had to be able to swallow.
Exclusion criteria
Patients excluded from the study were those who had had
hypercalcaemia, breast cancer or low-grade stromal endometrial
sarcoma, previous history of thrombosis or pulmonary embolism,
dysphagia or malabsorption, neutrophil count o1500mm
–3,
uncontrolled underlying comorbid disease, or any condition or
underlying comorbid disease that may alter compliance. Pregnant
or breastfeeding women were not eligible.
Randomisation and site coordination
Patients were randomly (1:1) assigned to treatment with megestrol
acetate or metronomic cyclophosphamide after registration
through the Centre Oscar Lambret Clinical Research Unit. We
used the method of random permuted block for randomisation.
Treatment plan
Patients received both treatments until progression (RECIST 1.0)
or intolerance, as complementary treatment of best supportive
care. There was no planned dose modification. In the metronomic
cyclophosphamide arm, as previously reported (Suvannasankha
et al, 2007), treatment consisted of cyclophosphamide 50mg b.i.d
orally. In the acetate megestrol arm, the treatment consisted of
acetate megetrol 320mg once daily orally, as previously reported
(Gebbia et al, 1996; De Conno et al, 1998; Westman et al, 1999;
Yavuzsen et al, 2005).
Study end points and data analysis
The primary efficacy end point was the progression-free rate (PFR)
at 2 months. Secondary end points were PFRs at 4 and 6 months,
toxicity according to the National Cancer Institute Common
Toxicity Criteria (Version 3.0), overall survival and median time to
progression, quality of life and rate of stable weight.
Consequently, during the study, patients underwent clinical and
haematological evaluations at days 1, 15, 30 and 60, and every 2
months thereafter. Disease was assessed by comparing unidimen-
sional tumour measurements (CT scan or MRI) on pre- and per-
treatment imaging studies at 2, 4 and 6 months. We assessed
response according to the RECIST 1.0. An independent third-party
radiologist panel reviewed imaging studies to verify all imaging
procedures carried out during the period of treatment with the
trial drug, to ensure consistent unbiased application of RECIST
1.0. We defined ‘stable weight’ as weight loss o10% in comparison
with baseline weight. Patients were surveyed at baseline, day 30
and day 60 using an auto-questionnaire (EORTC QLQC30 core
questionnaire (Aaronson et al, 1993)). For all parameters, we
carried out an intent-to-treat analysis.
Statistical considerations
The number of patients was initially calculated using an
‘Optimal Simon’s Design’ two-stage design (P0¼5%, P1¼20%,
a¼b¼10%). Planned inclusion was 44 patients per arm. This
design allowed the opening of the second stage if the PFR at 2
months was at least 1 out of 12. At the end of the second stage, if
the PFR at 2 months was at least 5 out of 44, the treatment was
defined as efficient.
Description of the populations used in the study was based on
percentages and their 95% confidence intervals (95% CI) for
categorical data, and median and extreme values for continuous
data. The Kaplan–Meier method was used to calculate the median
progression-free and overall survivals and their 95% CI.
The phase II randomised design did not allow a formal
comparison between both arms.
Ethical considerations
Study investigations were conducted after approval by the regional
ethics committee (‘Comite ´ de Protection des Patients Nord-Ouest
III’, date of approval) and after declaration to the French Health
Products Safety Agency (‘Agence Franc¸aise de Se ´curite ´ Sanitaire et
des Produits de Sante ´’, date of approval: June 2006). Informed
consent was obtained from each patient. This study was registered
in the European Clinical Trials Register (EudraCT No2006-003074-
10, June 2006). The study was conducted in agreement with the
Declaration of Helsinki and the International Conference on
Harmonisation of Good Clinical Practise guidelines.
RESULTS
Patient characteristics
Between September 2006 and January 2009, we enrolled 88
patients. Baseline characteristics were well balanced in both arms
(Table 1). All patients experienced progressive disease before
inclusion in the study. The median age was 66 years (CI: 57–71) in
the megestrol acetate arm and 61 (CI: 50–72) in the metronomic
cyclophosphamide arm. The median time between tumour
diagnosis and inclusion was 27 months (CI: 18–36) in the
megestrol acetate arm and 33 (CI: 24–42) in the metronomic
cyclophosphamide arm.
Toxicities
Table 2 describes all drug-related toxicities. Grade 3 and 4
toxicities were observed in the same range in both arms (4%, (CI:
1–6)). We observed a toxic death in the megestreol acetate arm: a
case of Budd–Chiari syndrome (hepatic venous outflow obstruc-
tion) in a patient with massive liver metastasis from uveal
melanoma. In the metronomic cyclophosphamide arm, we
observed interstitial pneumonia in a patient with peritoneal
metastasis from retroperitoneal liposarcoma, experiencing stable
disease after 6 months of treatment. The most frequent side effects
were oedema or hormonal and metabolic disorders in the
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smegestrol acetate arm, and nausea, vomiting or anaemia in the
metronomic cyclophosphamide arm. There was neither dose
reduction nor transient treatment break in both arms. In the
metronomic cyclophosphamide arm, one patient discontinued
treatment for toxicity (pneumonitis at 6 months). In the megestrol
acetate arm, two patients discontinued treatment for toxicity
(phlebitis).
Efficacy
At the end of the first stage, both treatments achieved statistical
requirement, allowing the commencement of the second stage (at
least one non-progression at 2 months among 12 patients). The
megestrol acetate arm failed to reach the desired threshold of
efficacy (Table 3). On the other hand, the metronomic cyclophos-
phamide arm successfully achieved the pre-defined level of efficacy
with a PFR at 2 months of 9 out of 44 (20%, (8–32)). In total, six
patients experienced stable disease at 4 months: one patient with
metastatic limb liposarcoma treated with megestrol acetate, three
patients with soft tissue sarcoma treated with metronomic
cyclophosphamide, one patient with metastatic squamous cell
skin cancer treated with metronomic cyclophosphamide and one
patient with renal cell cancer treated with metronomic cyclophos-
phamide. The median duration of treatment was 57 days (52–61)
with megestrol acetate and 58 (54–61) with metronomic cyclopho-
sphamide. The median time to progression was 60 days (59–61) in
both arms. Quality of life (Table 4) and weight stabilisation were
similar in both arms. The median overall survival was 144 days
(82–200) in the megestrol acetate arm and 195 (102–287) in the
metronomic cyclophosphamide arm (Figure 1).
DISCUSSION
We evaluated the efficacy and toxicity of two treatments
administered in cancer patients with a good PS and having
exhausted all available therapies under standard care. This
randomised clinical trial was ethical and conducted taking into
account clinical equipoise. Both treatments (metronomic cyclo-
phosphamide and megestrol acetate) gave comparable results in
term of secondary end points. Nevertheless, acetate megestrol was
responsible for the most severe side effects. Furthermore,
metronomic cyclophosphamide was the sole treatment that could
reach the predefined primary efficacy end point with a PFR at 2
months of 9 out of 44 and a PFR at 4 months of 4 out of 44.
Table 2 Treatment-related toxicities
Megestrol acetate Metronomic cyclophosphamide
G r a d e 1 2 3 4 512345
Fatigue 2 0 0 0 0 11000
Hot flashes 1 0 0 0 0 00000
Nausea 0 0 0 0 0 11000
Vomiting 0 0 0 0 0 10200
Anorexia 0 0 0 0 0 10000
Compulsive eating 1 0 0 0 0 00000
Hyper-triglyceridemia 0 0 1 0 0 00000
Epigastralgia 0 0 0 0 0 10000
Diarrhoea 0 1 0 0 0 00000
Aphtosis 0 0 0 0 0 10000
Anaemia 0 0 0 0 0 30000
Neutropaenia 0 0 0 0 0 10000
Phlebitis 0 1 0 0 1 00000
Gynecomastia 1 0 0 0 0 00000
Galactorrhoea 0 0 1 0 0 00000
Libido alteration 0 1 0 0 0 00000
Dysuria 0 0 0 0 0 01000
Interstitial pneumonia 0 0 0 0 0 01000
Oedema 1 2 0 0 0 00000
Total 5 5 2 0 1 10 4200







Men 29 (66%, (52–80)) 27 (61%, (47–75))




11 (25%, (12–38)) 11 (25%, (12–38))
Lung cancers 8 (18%, (6–29)) 7 (16%, (5–26))
Soft tissue sarcoma 9 (20%, (8–32)) 8 (18%, (6–29))
Melanomas 5 (11%, (2–20)) 4 (9%, (0–17))
Bladder cancers 4 (9%, (0–17)) 3 (6, (0–14))
Gastric cancers 1 (2%, (0–6)) 5 (11%, (2–20))
Hepatocarcinoma 2 (4%, (0–10)) 1 (2%, (0–6))
Unknown primaries 2 (4%, (0–10)) 1 (2%, (0–6))
Other tumours 2 (4%, (0–10)) 4 (9%, (0–17))
Metastasis
Liver 17 (38%, (24–53)) 16 (36%, (22–50))
Lung 17 (38%, (24–53)) 19 (43%, (28–57))
Extra-abdominal lymph
nodes
9 (20%, (8–32)) 10 (22%, (10–35))
Abdominal lymph nodes 5 (11%, (2–20)) 5 (11%, (2–20))
Pleura 4 (9%, (0–17)) 1 (2%, (0–6))
Adrenal gland 3 (6%, (0–14)) 6 (13%, (3–23))
Peritoneum 9 (20%, (8–32)) 2 (4%, (0–10))
Bone 3 (6, (0–14)) 3 (6, (0–14))
Brain 1 (2%, (0–6)) 1 (2%, (0–6))
Previously treated by
Surgery 31 (70%, (57–84)) 31 (70%, (57–84))
Radiotherapy 23 (52%, (37–67)) 22 (50%, (35–64))
Performance status
0 22 (50% (35–65)) 24 (54% (39–69))
1 17 (38% (18–45)) 17 (38% (24–53))
2 5 (12% (1–20)) 3 (3% (0–14))
Number of previous systemic treatment lines
0 0 1 (2%, (0–6))
1 12 (27%, (14–40)) 9 (20%, (8–32))
2 20 (45%, 30–60)) 21 (47%, (36–66))
3 8 (18%, (6–29)) 3 (6%, (0–14))
4 1 (2%, (0–6)) 5 (11%, (2–20))
X5 3 (6%, (0–14)) 5 (11%, (2–20))







4 (9%, (0–17)) 9 (20%, (8–32))
Progression-free rate at
4 months
1 (2%, (0–6)) 5 (11%, (2–20))
Progression-free rate at
6 months
1 (2%, (0–6)) 2 (4%, (0–10))
90-day mortality 12 (27%, (14–40)) 9 (20%, (8–32))
Stable weight at day 30 11 (25%, (12–38)) 6 (13%, (3–23))
Stable weight at day 60 6 (13%, (3–23)) 4 (9%, (0–17))
Stable QOL at day 30 22 (50%, (35–64)) 20 (45%, (30–60))
Stable QOL at day 60 10 (22%, (10–35)) 18 (41%, (26–55))
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sMegestrol acetate did not reach the primary efficacy end point.
Moreover, the rate of patients with stable weight was similar in
both arms. Moreover, we had observed that acetate megestrol was
the sole treatment responsible for oedemas that could overestimate
the weight stabilisation. Acetate megestrol had been associated
with compulsive eating and hypertriglyceridemia as a consequence
of its orexigen effect. We had observed thrombotic events in two
cases in this relatively small sample of patients. One of these
thrombotic events led to death. Considering all these facts, we did
not recommend administering megestrol acetate in such a
population.
This study had some limitations. The choice of acetate megestrol
as an internal comparator could be discussed, as endocrine
tumours have been excluded (breast cancer, low-grade stromal
endometrial sarcoma). Nevertheless, acetate megestrol is com-
monly administered in this patient population to maintain
appetite. Moreover, rare responses have been reported with such
hormonotherapy in patients with renal cancer and melanoma
(Ravaud et al, 2008). There is no consensual dose for megestrol
acetate (from 160 to 480mg per day) or oral cyclophosphamide
(more usually 50mg per day) is this population. Nevertheless,
Gebbia et al have shown that 480mg of megestrol acetate was not
superior to 320mg (Gebbia et al, 1996). The dose of 50mg b.i.d of
cyclophosphamide has been administered in a previous phase II
trial (Suvannasankha et al, 2007) in combination with thalidomide
and prednisone without significant toxicity. The study population
was a mix of patients with different tumours. The characteristics of
the study population were similar to those of patients enrolled in
phase I trials, with a 90-day mortality of approximately 20%
(Italiano et al, 2008; Penel et al, 2008; Arkenau et al, 2009). In the
current area of molecular-targeted therapies, one could argue the
very low level of evidence to investigate both treatments in non-
selected patients. Nevertheless, this study was pragmatic and
addressed a very common, daily clinical issue. We believe that
metronomic chemotherapy, especially metronomic cyclophospha-
mide, has been underevaluated. Many preclinical data and some
clinical evidence suggest that this treatment inhibits angiogenesis
(Bocci et al, 2003; Damber et al, 2005; Pietras and Hanahan, 2005;
Yap et al, 2005), and some biological markers (circulating vascular
endothelial growth factors, circulating endothelial cells, thrombos-
pondin and so on) warrant further investigations as potential
predictive factors (Bocci et al, 2003; Kieran et al, 2005; Munoz
et al, 2005; Dellapasqua et al, 2008). Some could argue that this
study did not formally establish the superiority of metronomic
cyclophospahmide over acetate megestrol. Nevertheless, the
purpose of randomised phase II trial is not to test such hypothesis
but to show in parallel the results of both treatment arms
(Cannistra, 2009). The ‘best’ arm is still chosen on the basis of the
predetermined tumour size, as previously carried out in single-arm
phase II trials. Randomisation minimises some pitfalls inherent to
single-arm phase II trials, especially selection biases. Thus, the
phase II randomised design leads to a double go–not go decision.
The results of this study are sufficiently consistent to stop the
evaluation of acetate megestrol in such a population and to favour
new studies with metronomic cyclophosphamide in the same
population. This study presents two strengths. All patients
included experienced progressive disease before inclusion. There-
fore, it is unlikely that the high rate of tumour stabilisation
observed with metronomic cyclophosphamide was a spontaneous
event. The second strength was the third-part CT-scan review that
confirms stable diseases.
Eight heavily pretreated patients with sarcoma received
metronomic cyclophosphamide in this study. We observed a
4-month non-progression rate of 3 out of 8. One patient
experienced a stable disease for more than 30 months. The
Table 4 Quality of live assessments (median and extreme values)
MA-arm baseline
(n¼44)










Physical functioning 5 (0–10) 6 (0–10) 8 (0–10) 4 (0–10) 4 (0–10) 7 (0–10)
Role functioning 2 (0–6) 3 (0–10) 5 (0–9) 3 (1–5) 4 (0–10) 5 (0–10)
Emotional
functioning
5 (1–9) 6 (0–9) 6 (0–9) 6 (2–10) 6 (2–10) 6 (2–10)
Cognitive
functioning
3 (0–5) 4(0–7) 4(1–8) 3 (1–6) 4 (1–8) 4 (1–9)
Social functioning 2 (0–5) 4 (0–8) 6 (2–8) 3 (0–7) 4 (0–10) 5 (0–10)
Quality of life 7 (4–7) 5 (2–7) 4 (0–7) 7 (7–5) 6 (1–7) 5 (0–7)
Fatigue 5 (0–9) 7 (0–10) 8 (2–10) 5 (0–10) 6 (0–10) 8 (0–10)
Nausea/vomiting 6 (0–10) 6 (2–10) 6 (0–10) 7 (0–10) 7 (0–10) 6 (0–10)
Pain 3 (0–5) 4 (0–10) 6 (3–10) 3 (1–6) 4 (2–9) 5 (0–9)
Dyspnoea 5 (1–8) 5 (0–9) 4 (2–9) 4 (0–8) 4 (2–10) 4 (2–9)
Sleep disturbance 8 (2–9) 7 (2–9) 8 (3–10) 7 (5–10) 8 (2–10) 7 (0–10)
Appetite loss 3 (0–6) 4 (0–10) 4 (1–9) 4 (1–6) 4 (0–8) 5 (0–10)
Constipation 2 (0–6) 3 (0–8) 4 (2–10) 3 (0–5) 4 (0–9) 4 (0–7)
Diarrhoea 1 (0–3) 1 (0–5) 1 (0–8) 2 (0–3) 2 (0–7) 2 (0–5)
Financial difficulty 4 (0–10) 6 (1–10) 6 (1–10) 5 (0–9) 5 (0–8) 6 (0–8)







0 200 400 600 800
Figure 1 Overall survival (in days). Black line: metronomic cyclopho-
sphamide, grey line: megestrol acetate.
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sobserved 4-month non-progression rate is in the range of results
defining a second-line treatment as effective according to the
EORTC recommendations (X40%) (Van Glabbeke et al, 2002). A
previous rat model study had shown promising antitumour
activity of metronomic cyclophosphamide administration in
lymphoma and sarcoma (Rozados et al, 2004). De Pas et al had
reported their single-centre experience of combined metronomic
chemotherapy (cyclophosphamide plus methotrexate) in 17
heavily pretreated sarcoma patients. The median time of treatment
was 3 months (range, 2–13), no grade 3–4 toxicity was noticed.
Eight patients experienced stable disease (median time to
progression 4 months, range 4–47þ). Out of these eight patients,
five experienced a progressing disease at the time of study entry.
Our findings, together with these previous data, justify a further
evaluation of metronomic cyclophosphamide in sarcoma patients.
On the contrary, no stable disease at 2 months was observed in
patients with gastrointestinal cancers that represent approximately
a third of enrolled patients.
Oral metronomic cyclophosphamide can be safely used on a
metronomic basis in such a population. The efficacy, low toxicity,
low cost (od 0.1 per day) and ease of administration of this
treatment justify further studies in patients having exhausted all
available therapies under standard care. We suggest that this
treatment may be used as an internal comparator in further
randomised phase II trials testing new options in some situations
without established or shared consensual therapy.
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